Schawk's Packages Deliver Less Revenue

Recs

15

Disney Buys Marvel!

...And David Gardner called it. He's up 1,334%! See what David's recommending that you buy NEXT!

Click here now to find out!

Branding used to be relatively simple: press a red-hot iron into the hides of your cows so everyone would know whose they were. For purveyors in today's marketplace, Schawk (NYSE: SGK) produces the fancy packaging and in-store displays that are essential for brand differentiation.

Schawk sells its custom packaging and marketing services to some of the biggest retailers of consumer goods. Among the many that rely on Schawk's services are health-care giants Pfizer (NYSE: PFE) and Merck (NYSE: MRK), computer hardware firm Hewlett-Packard (NYSE: HPQ), and other biggies, including Coca-Cola (NYSE: KO), Procter & Gamble (NYSE: PG), and Johnson & Johnson (NYSE: JNJ).

However, a solid client base hasn't been enough lately. Schawk has been implementing a ruthless cost-cutting strategy in response to weakening consumer spending, and the resulting lower sales. Investors got a good look at the numbers when Schawk reported third-quarter financial results last week.

Revenues fell 4% to $124.2 million from the year-ago period, but that's not surprising. Spending on marketing is typically among the first places where companies cut costs during economic downturns. The real Schawk-er was the slew of one-time setbacks in the form of acquisition integration expenses, restructuring costs, asset impairment charges, unrealized foreign currency losses, and a hefty income tax provision it had to set aside for its foreign operations. After those outlays, Schawk's quarterly losses were $6.7 million, or about $0.25 per share. In the year-ago period, earnings were positive by about the same amount.

What a Fool believes
Through a combination of restructuring some existing operations and closing others, Schawk expects to decrease its expense base by $13 million to $15 million in 2009. Employee layoffs should account for roughly 87% of that; the rest should come from lower leasing and depreciation costs. While it may be no consolation to those losing their jobs, investors might find encouragement in the company's long-term prospects. With its operating cash flows and revolving line of credit, Schawk expects to stay sufficiently financed to continue paying dividends and repurchasing stock. But those watching may want to keep an eye on its leverage. Debt as a percentage of equity inched up to 40%, from 35%, after it borrowed on its credit line to buy back 636,000 shares last quarter.

Consumer-products packaging, Schawk's core business, didn't suffer as badly as its advertising/retail and entertainment segments, and much of the sales decline was concentrated in new design and innovation activities, where growth will most likely resume when the economy recovers. When that happens, Schawk could emerge a much leaner and meaner machine.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Pfizer and Johnson & Johnson are Motley Fool Income Investor selections. Pfizer and Coca-Cola are Motley Fool Inside Value recommendations. The Fool owns shares of Pfizer. Try any of our Foolish newsletters today, free for 30 days, and check out our in-depth analysis of all the stock recommendations in our market-beating newsletter portfolios.

Chris Jones does not own shares in any of the companies mentioned. The Fool's disclosure policy accompanies this little piggy to market once a week.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 783774, ~/Articles/ArticleHandler.aspx, 11/10/2009 9:15:51 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:00 PM
JNJ $60.75 Up +0.45 +0.75%
Johnson & Johnson CAPS Rating: *****
PG $61.85 Up +0.81 +1.33%
The Procter & Gamb… CAPS Rating: *****
SGK $10.58 Down -0.08 -0.75%
Schawk, Inc. CAPS Rating: *
PFE $17.43 Up +0.47 +2.77%
Pfizer, Inc. CAPS Rating: ****
KO $55.48 Up +0.99 +1.82%
The Coca-Cola Comp… CAPS Rating: ****
HPQ $49.99 Up +0.83 +1.69%
Hewlett-Packard Co… CAPS Rating: ***
MRK $33.43 Up +0.84 +2.58%
Merck & Co., Inc. CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Intellectual property: Intellectual property is the broadly defined category of assets that typically includes brand names, trademarks, copyrights, patents, knowhow, trade secrets, etc. They are barriers to entry for competitors.

Want to learn more or edit this definition?
Click here to read more!